Inve US ▾
BEBEAT

HeartBeam (BEAT) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 13, 2026

Source: earnings call transcript

Executive summary

HeartBeam Q2 FY26 — Heart Attack Detection Pre-Sub Submitted, Commercial Rollout Underway

HeartBeam is rapidly advancing its heart attack detection program, submitting its pre-submission to the FDA and seeing strong clinical trial enrollment. The initial commercial launch in the concierge market is gaining traction with workflow integration, and the company has significantly reduced its operating cash burn, extending its financial runway. Management remains focused on core priorities and expects accelerated revenue growth in the second half of the year.

Highlights

5

  • Submitted pre-submission to FDA for heart attack detection indication on call date, advancing regulatory pathway.

  • Net cash used in operating activities decreased 7% QoQ to $3.3 million in Q2 FY26.

  • Cash runway extended further into 2027 following $11.5 million common stock financing in April 2026.

  • ALIGN-ACS pilot study completed enrollment in less than 4 months with 134 patients, results accepted for TCT presentation.

  • HEADSTART-ACS pilot study surpassed 50% enrollment in less than 3 months for its 500-patient study.

Concerns

2

  • Net loss for Q2 FY26 was $5 million, including $0.9 million in one-time items related to leadership transition.

  • Initial commercial rollout metrics are still in the 'thousands of patients', with detailed metrics to be provided after Q3.

Guidance & targets

CategoryTargetConfidence
Operating Cash Flow
below $2.5 million
high materiality
High
Full-Year Operating Cash Outflows
below $14 million
high materiality
High
Pivotal Trial Start for Heart Attack Detection
before year-end
high materiality
High
Commercial Order Flow Magnitude
increasing magnitude
medium materiality
Medium
Patients for Cash Flow Positive
sub-30,000 patients
high materiality
High

Product announcements

ProductTypeDetails
12-lead EKG Patchmilestone
Acoustic Sensors Technologyroadmap
Fluid Monitoring Technologyroadmap

Risks & headwinds

One-time costs related to leadership transition Q2 FY26, with some related noise in Q3 FY26

$0.9 million in Q2 FY26 net loss (comprising $0.6M non-cash stock-based comp and $4.3M severance accrual)

Mitigation:These are one-time in nature, underlying net loss is lower; company focused on reducing cost profile.

Increased operating spend due to pivotal MI study Before year-end 2026 and into 2027

May increase spend beyond baseline Q4 FY26 operating cash flow of sub-$2.5 million

Mitigation:Framed as a 'great problem to have' due to positive trends in enrollment and FDA collaboration; partially offset by cash receipts from commercial launch.

What to watch in Q3 FY26

Pivotal Trial Start for Heart Attack Detection

Before year-end 2026
Current Pre-sub submitted to FDA today (Aug 13, 2026)
Target Trial initiated

Why it matters

Initiation of the pivotal trial is a critical step towards FDA approval for heart attack detection, which is the company's top strategic priority and a major value driver.

But quite frankly, based on the fact that there were predicates that we identified, and it's a 510(k), I wouldn't expect the trial to be of an exorbitant number. Based on the fact and the proof statements of the trials that we have previously run that have all been completed ahead of their schedules, I think we feel cautiously optimistic we could start the trial before year-end.

Find out whether BEAT delivers this. Inve re-checks your case every morning.

Q&A highlights

Clarify the strategic shift to licensing data and target partners/applications.

Management clarified that 'licensing' was an overstatement; the focus is on partnerships with integrated systems for workflow integration, not pure data licensing. The Indonesia trial might evolve into a licensing strategy, but it's yet to be determined.

“I think licensing may have been a bit of kind of an overstatement because it's embedded into the concept, basically the concept and the initiative of working with the integrated systems to incorporate our technology into their workflow.”

asked by Jeremy Perlman · answered by Richard Ferrari

2 min read 5 chapters

Detailed narrative

Heart Attack Detection Progress

HeartBeam has made significant strides in its heart attack detection program, submitting its pre-submission to the FDA on the call date via the 510(k) pathway. Clinical validation efforts are ahead of schedule, with the ALIGN-ACS pilot study completing enrollment of 134 patients in under four months and its results accepted for presentation at TCT. The HEADSTART-ACS pilot study, a 500-patient study supported by the Indonesian government, has already surpassed 50% enrollment in less than three months. An upcoming JACC article will further demonstrate the accuracy of HeartBeam's algorithm in identifying heart attacks.

Product Platform & Intellectual Property

The company's core technology, utilizing tri-core 3D signal reconstruction, is protected by 25 issued patents worldwide. This proprietary technology enables the development of a platform with three distinct form factors: the Card for post-discharge monitoring, the Patch for emergency room and in-hospital monitoring, and the Remote Unit for access in remote locations, currently being used in Indonesia. The technology is clinically validated and FDA cleared for arrhythmic assessment, with ongoing efforts to expand into heart attack detection.

Commercial Strategy & Early Traction

HeartBeam's initial commercial launch is underway, focusing on the concierge vertical, which includes approximately 1.9 million patients, with hundreds of thousands identified as cardiac-oriented. The company has signed agreements in target markets including New York, Dallas, South Florida, and Southern California, with initial orders shipped and patients onboarding. A key learning has been to streamline workflow by integrating HeartBeam into new patient intake processes at concierge practices, which is expected to accelerate adoption and lead to an increasing magnitude of order flow by the end of Q3 FY26.

Financial Discipline & Runway Extension

The company demonstrated strong financial discipline in Q2 FY26, reducing net cash used in operating activities by 7% quarter-over-quarter to $3.3 million. This was achieved through tightly managed costs, efficiency gains, and executives electing to receive shares in lieu of cash for bonuses. Following an $11.5 million common stock financing in April 2026, HeartBeam reported $8.8 million in cash, cash equivalents, and restricted cash as of June 30, 2026, extending its cash runway further into 2027. The baseline operating cash flow is projected to be below $2.5 million per quarter by Q4 FY26, with full-year operating cash outflows expected to be below $14 million.

Future Innovations

HeartBeam continues to innovate, securing two new patents for future applications of its technology. One patent is for acoustic sensors, designed to provide insights into heart valve performance. The other is for fluid monitoring capabilities, utilizing impedance to detect fluid increases in patients, particularly beneficial for managing congestive heart failure and potentially reducing emergency room visits. These innovations highlight the platform's versatility and long-term growth potential beyond current indications.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.